A Schneider, B Tourlonias, L Cormier, E Mourey, N Koutlidis, E Delorme, J Pasquale, I Kermarec, A-D Foahom-Kamwa, V Bonniaud
INTRODUCTION: Since 2014, OnabotulinumtoxinA Botox® (Allergan, Inc., Irvine, USA) represents a new therapeutic option for second-line treatment of idiopathic overactive bladder. The purpose of the current study was to evaluate practices of surgeons using onabotulinium toxin (BoNTA) in this indication. MATERIAL AND METHODS: All urogynecology centers of the country were asked in order to list all patients who were treated since marketing autorisation. Patient symptoms, previous treatments, paraclinic evaluations, data of surgery and the characteristics of the follow up were collected and analyzed...
March 2018: Progrès en Urologie